BDRX Valuation

Biodexa Pharmaceuticals PLC

Add to Watchlist

Advanced Chart

5.540

+0.07(1.280%)1D

Overview
Forecast
Valuation
Earnings

BDRX Relative Valuation

BDRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BDRX is overvalued; if below, it's undervalued.

Historical Valuation

Biodexa Pharmaceuticals PLC (BDRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -52.31. The fair price of Biodexa Pharmaceuticals PLC (BDRX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.51

Fair

-10.13

Trailing

Forward

0.00

EV/EBITDA

Biodexa Pharmaceuticals PLC. (BDRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.41. The thresholds are as follows: Strongly Undervalued below -6.91, Undervalued between -6.91 and -4.16, Fairly Valued between 1.35 and -4.16, Overvalued between 1.35 and 4.10, and Strongly Overvalued above 4.10. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.16

EV/EBIT

Biodexa Pharmaceuticals PLC. (BDRX) has a current EV/EBIT of -0.16. The 5-year average EV/EBIT is -0.22. The thresholds are as follows: Strongly Undervalued below -1.25, Undervalued between -1.25 and -0.73, Fairly Valued between 0.30 and -0.73, Overvalued between 0.30 and 0.81, and Strongly Overvalued above 0.81. The current Forward EV/EBIT of -0.16 falls within the Historic Trend Line -Fairly Valued range.

0.00

Biodexa Pharmaceuticals PLC. (BDRX) has a current PS of 0.00. The 5-year average PS is 46.53. The thresholds are as follows: Strongly Undervalued below -130.19, Undervalued between -130.19 and -41.83, Fairly Valued between 134.89 and -41.83, Overvalued between 134.89 and 223.25, and Strongly Overvalued above 223.25. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.17

P/OCF

Biodexa Pharmaceuticals PLC. (BDRX) has a current P/OCF of -0.17. The 5-year average P/OCF is -0.10. The thresholds are as follows: Strongly Undervalued below -0.40, Undervalued between -0.40 and -0.25, Fairly Valued between 0.05 and -0.25, Overvalued between 0.05 and 0.20, and Strongly Overvalued above 0.20. The current Forward P/OCF of -0.17 falls within the Historic Trend Line -Fairly Valued range.

-0.16

P/FCF

Biodexa Pharmaceuticals PLC. (BDRX) has a current P/FCF of -0.16. The 5-year average P/FCF is -0.05. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and -0.17, Fairly Valued between 0.07 and -0.17, Overvalued between 0.07 and 0.19, and Strongly Overvalued above 0.19. The current Forward P/FCF of -0.16 falls within the Historic Trend Line -Fairly Valued range.

Biodexa Pharmaceuticals PLC (BDRX) has a current Price-to-Book (P/B) ratio of 0.03. Compared to its 3-year average P/B ratio of 0.54 , the current P/B ratio is approximately -93.95% higher. Relative to its 5-year average P/B ratio of 0.32, the current P/B ratio is about -89.86% higher. Biodexa Pharmaceuticals PLC (BDRX) has a Forward Free Cash Flow (FCF) yield of approximately -468.17%. Compared to its 3-year average FCF yield of -302.10%, the current FCF yield is approximately 54.97% lower. Relative to its 5-year average FCF yield of -200.20% , the current FCF yield is about 133.85% lower.

0.03

P/B

Median3y

0.54

Median5y

0.32

-468.17

FCF Yield

Median3y

-302.10

Median5y

-200.20

Competitors Valuation Multiple

The average P/S ratio for BDRX's competitors is 0.03, providing a benchmark for relative valuation. Biodexa Pharmaceuticals PLC Corp (BDRX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BDRX.O

Biodexa Pharmaceuticals PLC

Universe Pharmaceuticals Inc

Psyence Biomedical Ltd

Redhill Biopharma Ltd

0.08

-90.21%

3.10M

Performance Decomposition

Market capitalization of BDRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BDRX in the past 1 year is driven by Unknown.